Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study
Phase of Trial: Phase II
Latest Information Update: 08 May 2017
Price : $35 *
At a glance
- Drugs Dabrafenib (Primary) ; Vemurafenib
- Indications Malignant melanoma
- Focus Adverse reactions
- 02 May 2017 Planned End Date changed from 1 Jun 2016 to 1 Dec 2017.
- 02 May 2017 Status changed from recruiting to discontinued because second cohort not opened because Simon-Two_Step model failed
- 07 Jun 2016 Results from phase IIa portion of the study presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.